Replies to post #95541 on Biotech Values

[drbio45]

David Hung took three Dimebon's and remembered that those trials were on going and they should be halted.

the drug was good for something

[DewDiligence]

On first inspection, MDVN/PFE’s decision seems counterintuitive. The Dimebon study that failed (CONNECTION) was in mild-to-moderate AD, but the remaining Dimebon trial in mild-to-moderate AD (CONCERT) is the only one of the three ongoing AD trials they are keeping. Perhaps the explanation is that CONCERT is the only trial that has a chance to increase sales of Aricept.